EGPA - EOSINOPHILIC GRANULOMATOSIS WITH POLYANGIITIS
Clinical trials for EGPA - EOSINOPHILIC GRANULOMATOSIS WITH POLYANGIITIS explained in plain language.
Never miss a new study
Get alerted when new EGPA - EOSINOPHILIC GRANULOMATOSIS WITH POLYANGIITIS trials appear
Sign up with your email to follow new studies for EGPA - EOSINOPHILIC GRANULOMATOSIS WITH POLYANGIITIS, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New hope for rare blood vessel disease: drug aims to cut steroids and keep patients stable
Disease control OngoingThis study tests a drug called tezepelumab in 42 adults with EGPA, a rare disease that causes inflammation in blood vessels, often leading to asthma and nerve damage. The goal is to see if the drug can help patients achieve remission (no active disease) while taking very low dose…
Matched conditions: EGPA - EOSINOPHILIC GRANULOMATOSIS WITH POLYANGIITIS
Phase: PHASE2 • Sponsor: Imperial College London • Aim: Disease control
Last updated May 26, 2026 12:01 UTC
-
Proteomics may reveal hidden clues to rare disease treatment success
Knowledge-focused ENROLLING_BY_INVITATIONThis study aims to identify proteins in blood, saliva, and sputum that can help doctors predict organ damage and how well patients with EGPA (a rare inflammatory disease) or severe asthma respond to the drug mepolizumab. Researchers will analyze samples from 90 participants befor…
Matched conditions: EGPA - EOSINOPHILIC GRANULOMATOSIS WITH POLYANGIITIS
Phase: PHASE4 • Sponsor: Azienda Ospedaliero Universitaria di Cagliari • Aim: Knowledge-focused
Last updated May 26, 2026 11:59 UTC